317 related articles for article (PubMed ID: 24810750)
1. Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus.
Schroeder U; Lauten M; Stichtenoth G; Gebhard MP; Buchholz M; Kaiser MM
Klin Padiatr; 2014 Nov; 226(6-7):362-8. PubMed ID: 24810750
[TBL] [Abstract][Full Text] [Related]
2. A not so harmless mass: Kaposiform hemangioendothelioma complicated by a Kasabach-Merritt phenomenon.
Tribolet S; Hoyoux C; Boon LM; Cheruy C; Demarche M; Jamblin P; Roberti A; Willemaers V; Viellevoye R; Rigo V; Broux I
Arch Pediatr; 2019 Sep; 26(6):365-369. PubMed ID: 31353149
[TBL] [Abstract][Full Text] [Related]
3. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options.
Schmid I; Klenk AK; Sparber-Sauer M; Koscielniak E; Maxwell R; Häberle B
World J Pediatr; 2018 Aug; 14(4):322-329. PubMed ID: 30054848
[TBL] [Abstract][Full Text] [Related]
4. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
5. Mediastinal kaposiform hemangioendothelioma and Kasabach-Merritt phenomenon in a patient with no skin changes and a normal chest CT.
Wallenstein MB; Hole MK; McCarthy C; Fijalkowski N; Jeng M; Wong WB
Pediatr Hematol Oncol; 2014 Sep; 31(6):563-7. PubMed ID: 24047193
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome for kaposiform hemangioendothelioma: A report of two cases.
Schaefer BA; Wang D; Merrow AC; Dickie BH; Adams DM
Pediatr Blood Cancer; 2017 Feb; 64(2):284-286. PubMed ID: 27701822
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
8. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
9. Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon.
Pati S; Das MK; Rana A; Das E; Sarkar S; Sherpa N; Datta S
Indian J Pediatr; 2021 Nov; 88(11):1142-1144. PubMed ID: 34106442
[TBL] [Abstract][Full Text] [Related]
10. Kaposiform hemangioendothelioma without cutaneous involvement.
Ji Y; Chen S; Li L; Yang K; Xia C; Li L; Yang G; Kong F; Lu G; Liu X
J Cancer Res Clin Oncol; 2018 Dec; 144(12):2475-2484. PubMed ID: 30293120
[TBL] [Abstract][Full Text] [Related]
11. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
12. Prenatal suspicion of Kaposiform hemangioendo-thelioma in siblings: different clinical manifestation and emergency relief.
Rapp M; Rapp M; Berg C; Knoepfle G; Müller AM; Bartmann P; Müller AM
Klin Padiatr; 2012 Oct; 224(6):390-1. PubMed ID: 23143766
[No Abstract] [Full Text] [Related]
13. The clinical spectrum of kaposiform hemangioendothelioma and tufted angioma.
Croteau SE; Gupta D
Semin Cutan Med Surg; 2016 Sep; 35(3):147-52. PubMed ID: 27607323
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
17. Additive value of transarterial embolization to systemic sirolimus treatment in kaposiform hemangioendothelioma.
Brill R; Uller W; Huf V; Müller-Wille R; Schmid I; Pohl A; Häberle B; Perkowski S; Funke K; Till AM; Lauten M; Neumann J; Güttel C; Heid E; Ziermann F; Schmid A; Hüsemann D; Meyer L; Sporns PB; Schinner R; Schmidt VF; Ricke J; Rössler J; Kapp FG; Wohlgemuth WA; Wildgruber M
Int J Cancer; 2021 May; 148(9):2345-2351. PubMed ID: 33231291
[TBL] [Abstract][Full Text] [Related]
18. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
19. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.
Maza-Morales M; Valdés-Loperena S; Durán-McKinster LC; García-Romero MT
Pediatr Dermatol; 2023; 40(3):440-445. PubMed ID: 36716766
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
